Our results showed that the serum DNA methylation levels of three genes (ADCY2, MAP2K1 and AKT1) in the chemokine signaling pathway were correlated with AD, and expressions of MAP2K1 and AKT1 were both verified differently in the brain of AD, which could be used as serum candidate markers for AD. This evidence concerns the gene MAP2K1 and Alzheimer disease.